Bibliography
- Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;339:342-4
- Heuschmann PU, Kolominsky-Rabas PL, Roether J, et al. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. J Am Med Assoc 2004;292:1831-8
- Hankey GJ, Jamrozik K, Broadhurst RJ, et al. Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke 1998;29:2491-500
- Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73
- Baron JC, Warach S. Imaging. Stroke 2005;36:196-9
- Jahan R. Hyperacute therapy of acute ischemic stroke: intraarterial thrombolysis and mechanical revascularization strategies. Tech Vasc Interv Radiol 2005;8:87-91
- Schabitz WR, Fisher M. Perspectives on neuroprotective stroke therapy. Biochem Soc Trans 2006;34:1271-6
- The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-8
- Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke Monitoring Study (SITS-MOST). Lancet 2007;369:275-82
- Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). J Am Med Assoc 1995;274:1017-25
- Hacke W, Kaste M, Fieschi C, et al. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-51
- Clark WN, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial, Alteplase Thrombolysis for acute noninterventional therapy in ischemic stroke. J Am Med Assoc 1999;282:2019-26
- Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-74
- Hacke W, Kaste M, Bluhmki E, et al. (for the ECASS Investigators). Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. N Engl J Med 2008;359:1317-29
- Fisher M, Bastan B. Treating acute ischemic stroke. Curr Opin Drug Discov Devel 2008;11:626-32
- Ribo M, Molina CA, Rovira A, et al. Safety and efficacy of intravenous tissue plasminogen activator in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke 2005;36:602-06
- Schellinger PD, Thomalla G, Fiehler J, et al. MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: an analysis of 1210 patients. Stroke 2007;38:2640-45
- Davis SM, Donnan GA, Parsons MW, et al. Effects of alteplase beyond 3h after stroke onset in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomized trial. Lancet Neurol 2008;7:299-399
- Furlan AJ, Eyding D, Albers GW, et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006;37:1227-31
- Forest Laboratories Inc. Topline results of phase III study in acute ischemic stroke (DIAS-2) do not demonstrate difference between desmoteplase and placebo. Press Release 31 May 2007
- Warach S. Clinical benefit of desmoteplase treatment in patients with moderate to severe stroke: Further results of the DIAS-2 Trial. International Stroke Conference 2008, New Orleans, LA, USA (2008): LBP2 Meeting dates: 20-22 February 2008.
- Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. J Am Med Assoc 1999;282:2003-11
- Ogawa A, Mori E, Minematsu K, et al. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: The middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke 2007;38:2633-39
- Lisboa RC, Jovanovic BD, Alberts MJ. Analysis of the safety and efficacy on intra-arterial thrombolytic therapy in ischemic stroke. Stroke 2002;33:2866-71
- Lindsberg PJ, Mattle HP. Therapy of basilar artery occlusion: a systematic analysis comparing intra-arterial and intravenous thrombolysis. Stroke 2006;37:922-28
- Mandava P, Kent TA. Intra-arterial therapies for acute ischemic stroke. Neurology 2007;68:2132-39
- IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: The Interventional Management of Stroke Study. Stroke 2004;35:904-11
- The IMS II Trial Investigators. The Interventional Management of Stroke (IMS) Study. Stroke 2007;38:2127-35
- Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: Results of the MERCI trial. Stroke 2005;36:1432-40
- Smith WS, Sung G, Saver J, et al. Mechanical thrombectomy for acute ischemic stroke: Final results of the Multi MERCI trial. Stroke 2008;39:1205-11
- The Penumbra Stroke Trial. Penumbra Inc, Alameda, CA, USA. Available from: www.penumbrainc.com/physicians/clinical-trial
- Fisher M, Ratan R. New perspectives on developing acute stroke therapy. Ann Neurol 2003;53:10-20
- Lo EH, Moskowitz MA, Jacobs TP. Exciting, radical, suicidal: how brain cells die after stroke. Stroke 2005;36:189-92
- Hossman KA. Pathophysiology and therapy of experimental stroke. Cell Mol Neurobiol 2006;26:1055-81
- Lo EH. Experimental models, neurovascular mechanisms and translational issues in stroke research. Br J Pharmacol 2008;153:S396-405
- Bardutzky J, Meng X, Bouley J, et al. Effects of intravenous dimethyl sulfoxide on ischemia evolution in a rat permanent occlusion model. J Cereb Blood Flow Metab 2005;25:968-77
- Ning M, Furie KL, Koroshetz WJ, et al. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology 2006;66:1550-55
- Belayev L, Busto R, Zhao W, et al. Effect of delayed albumin hemodilution on infarction volume and brain edema after transient middle cerebral artery occlusion in rats. J Neurosurg 1997;87:595-601
- Belayev L, Zhao W, Pattany PM, et al. Diffusion-weighted magnetic resonance imaging confirms marked neuroprotective efficacy of albumin therapy in focal cerebral ischemia. Stroke 1998;29:2587-99
- Belayev L, Liu Y, Zhao W, et al. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 2001;32:553-60
- Ginsberg MD, Belayev L, Bazan NG, et al. Albumin-based neurotherapeutics for acute ischemic stroke: from bench to bedside. In: Krieglstein J, Klumpp S, Editors, Pharmacology of Cerebral Ischemia, Medpharm Scientific Publishers, Stuttgart, Germany; 2004. p. 421-33
- Wayner DD, Burton GW, Ingold KU, et al. Quantitative measurement of the total, peroxyl radical-trapping antioxidant capability of human blood plasma by controlled peroxidation. The important contribution made by plasma proteins. FEBS Lett 1985;187:33-7
- He P, Curry FE. Albumin modulation of capillary permeability: role of endothelial cell [Ca2+]i. Am J Physiol 1993;265:H74-82
- Huh PW, Belayev L, Zhao W, et al. The effect of high-dose albumin therapy on local cerebral perfusion after transient focal cerebral ischemia in rats. Brain Res 1998;804:105-13
- Belayev L, Pinard E, Nallet H, et al. Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses. Stroke 2002;33:1077-84
- Rodriguez de Turco EB, Belayev L, Liu Y, et al. Systemic fatty acid responses to transient focal cerebral ischemia: influence of neuroprotectant therapy with human albumin. J Neurochem 2002;83:515-24
- Palesch YY, Hill MD, Ryckborst KJ, et al. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke. II. Neurological outcome and efficacy-analysis. Stroke 2006;37:2107-14
- Ginsberg MD, Hill MD, Palesch YY, et al. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke. I. Physiological responses and safety results. Stroke 2006;37:2100-06
- Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 2008;55:363-89
- Ovbiagele B, Kidwell CS, Starkman S, et al. Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep 2003;3:9-20
- Izumi Y, Roussel S, Pinard E, et al. Reduction of infarct volume by magnesium after middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 1991;11:1025-30
- Yang Y, Li Q, Ahmad F, et al. Survival and histological evaluation of therapeutic window of post-ischemia treatment with magnesium sulfate in embolic stroke model of rat. Neurosci Lett 2000;285:119-22
- Westermaier T, Zausinger S, Baethmann A, et al. Dose finding study of intravenous magnesium sulphate in transient focal cerebral ischemia in rats. Acta Neurochir (Wien) 2005;147:525-32
- Marinov MB, Harbaugh KS, Hoopes PJ, et al. Neuroprotective effects of preischemia intraarterial magnesium sulfate in reversible focal cerebral ischemia. J Neurosurg 1996;85:117-24
- Meloni BP, Zhu H, Knuckey NW. Is magnesium neuroprotective following global and focal cerebral ischaemia? A review of published studies. Magn Res 2006;19:123-37
- Stewart D, Marder VJ, Starkman S, et al. Magnesium sulfate neither potentiates nor inhibits tissue plasminogen activator-induced thrombolysis. J Thromb Haemost 2006;4:1575-79
- Muir KW, Lees KR, Ford I, et al. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet 2004;363:439-45
- Saver JL, Kidwell C, Eckstein M, et al. Prehospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial. Stroke 2004;35:e106-08
- Internet Stroke Center, Stroke Trials Registry. 2007. Available from: http://www.strokecenter.org/trials/index.aspx.
- FAST-MAG Trial website. 2007. Available from: http://www.fastmag.info/p_summ.htm.
- Sherman DG, Atkinson RP, Chippendale T, et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA 2000;283:2395-403
- Hennerici MG, Kay R, Bogousslavsky J, et al. Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial. Lancet 2006;368:1871-8
- Ntaios G, Savopoulos C, Chatzinikolaou A, et al. The neuroprotective role of erythropoietin in the management of acute ischaemic stroke: from bench to bedside. Acta Neurol Scand 2008;118:362-368.
- NIH Clinical Trials Registry. 2008. Available from: www.clinicaltrials.gov.
- Schabitz WR, Schneider A. New targets for established proteins: exploring G-CSF for the treatment of stroke. Trends Pharmacol Sci 2007;28:157-61
- Schneider A, Kruger C, Steigleder T, et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 2005;115:569-73
- Gibson CL, Bath PM, Murphy SP, et al. G-CSF reduces infarct volume and improves functional outcome after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab 2005;25:431-9
- Komine-Kobayashi M, Zhang N, Liu M, et al. Neuroprotective effect of recombinant human granulocyte colony stimulating factor in transient focal ischemia of mice. J Cereb Blood Flow Metab 2006;26:402-13
- Schabitz WR, Kollmar R, Schwaninger M, et al. Neuroprotective effect of granulocyte colony stimulating factor after focal cerebral ischemia. Stroke 2003;34:745-51
- Schneider A, Wysocki R, Pitzer C, et al. An extended window of opportunity for G-CSF treatment in cerebral ischemia. BMC Biol 2006;4:36
- Shyu WC, Lin SZ, Yang HI, et al. Functional recovery of stroke rats induced by granulocyte colony stimulating factor-stimulated stem cells. Circulation 2004;110:1847-54
- Minnerup J, Heidrich J, Wellman J, et al. Meta-Analysis of the efficacy of granulocyte colony stimulating factor in the animal models of focal cerebral ischemia. Stroke 2008;39:1855-61
- Rogalweski A, Schneider A, Ringelstein EB, et al. Toward a multimodal neuroprotective treatment of stroke. Stroke 2006;37:1129-36
- Shyu WC, Lin SZ, Lee CC, et al. Granulocyte colony stimulating factor for acute ischemic stroke : a randomized controlled trial. CMAJ 2006;174:927-33
- Sprigg N, Bath PM, Zhao L, et al. Granulocyte colony stimulating factor mobilizes bone marrow stem cells in patients with subacute ischemic stroke: the Stem cell Trial of recovery Enhancement after Stroke (STEMS) pilot randomized, controlled trial (ISRCTN 16784092). Stroke 2006;37:2979-83
- Secades JJ, Lorenzo JL. Citicoline: pharmacological profile and clinical review, 2006 update. Methods Find Exp Clin Pharmacol 2006;28(Suppl B):1-56
- Davalos A, Castillo J, Alvarez-Sabin J, et al. Oral citicoline in acute ischemic stroke : an individual patient data pooling analysis of clinical trials. Stroke 2002;33:2850-7
- Fisher M, Albers GW, Donnan GA, et al. Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry roundtable. Stroke 2005;36:1808-13
- Donnan GA. A new road map for neuroprotection. Stroke 2008;39:242-48
- Phan TG, Donnan GA, Davis SM, et al. Proof-of-principle phase II MRI studies in stroke : Sample size estimates from dichotomous and continuous data. Stroke 2006;37:2521-25
- Fisher M, Cheung K, Howard G, et al. New pathways forevaluating potential acute stroke therapies. Int J Stroke 2006;1:52-8
- Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. N Engl J Med 2006;354:588-600
- Shuaib A, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007;357:562-71